Clinical Trial Detail

NCT ID NCT04203316
Title Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Children's Oncology Group
Indications

acute myeloid leukemia

Therapies

Enasidenib

Age Groups: adult child

Additional content available in CKB BOOST